LivaNova (NASDAQ:LIVN) Downgraded to “Buy” Rating by StockNews.com

StockNews.com cut shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a buy rating in a research note released on Thursday morning.

Other analysts also recently issued reports about the stock. Robert W. Baird increased their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday. Barclays lowered their target price on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of LivaNova in a research report on Monday, March 17th. Mizuho lowered their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Finally, Stifel Nicolaus reduced their target price on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and an average price target of $59.17.

LivaNova Trading Down 0.0 %

Shares of NASDAQ LIVN opened at $44.06 on Thursday. The business has a 50 day simple moving average of $37.89 and a 200 day simple moving average of $45.15. LivaNova has a 52 week low of $32.48 and a 52 week high of $63.57. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of 104.90 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. Russell Investments Group Ltd. lifted its holdings in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after buying an additional 219 shares during the last quarter. Summit Investment Advisors Inc. increased its position in LivaNova by 1.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after acquiring an additional 289 shares during the period. Central Pacific Bank Trust Division raised its stake in LivaNova by 7.0% during the 1st quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company’s stock valued at $173,000 after purchasing an additional 290 shares during the last quarter. CWM LLC boosted its holdings in LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after purchasing an additional 299 shares during the period. Finally, Xponance Inc. grew its position in LivaNova by 6.1% in the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after purchasing an additional 445 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.